Advertisement
Home »

PARP inhibitor predictive value of the Leuven HRD test compared with Myriad MyChoice CDx PLUS HRD on 468 ovarian cancer patients from the PAOLA-1/ENGOT-ov25 trial.

May 29, 2023

ABOUT THE EXPERTS

  • Liselore Loverix

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium; KU Leuven VIB Center for Cancer Biology, Lab of Translational Genetics, Leuven, Belgium.

    Ignace Vergote

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Pieter Busschaert

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Adriaan Vanderstichele

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Tom Venken

    KU Leuven VIB Center for Cancer Biology, Lab of Translational Genetics, Leuven, Belgium.

    Bram Boeckx

    KU Leuven VIB Center for Cancer Biology, Lab of Translational Genetics, Leuven, Belgium.

    Philipp Harter

    Department of Gynaecology & Gynaecologic Oncology, Ev. Kliniken Essen-Mitte, Essen, and Arbeitsgemeinschaft Gynäkologische Onkologie (AGO), Germany.

    Hilde Brems

    University Hospitals Leuven, KU Leuven, Department of Human Genetics, Leuven, Belgium.

    Els Van Nieuwenhuysen

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Sandro Pignata

    Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione G. Pascale, and Multicenter Italian Trials in Ovarian Cancer and Gynecologic Malignancies (MITO), Naples, Italy.

    Thaïs Baert

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Antonio Gonzalez-Martin

    Department of Medical Oncology, Clínica Universidad de Navarra, Program in Solid Tumors (CIMA), Pamplona, and Grupo Español de Investigación en Cáncer de Ovario (GEICO), Spain.

    Sileny Han

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Christian Marth

    Department of Obstetrics and Gynecology, Medical University Innsbruck, Innsbruck, and AGO Austria, Austria.

    Patrick Neven

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Nicoletta Colombo

    University of Milan-Bicocca and European Institute of Oncology IRCCS, and Mario Negri Gynecologic Oncology Group (MANGO), Milan, Italy.

    Patrick Berteloot

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Johanna Mäenpää

    Department of Obstetrics and Gynecology and Cancer Center, Tampere University and University Hospital, Tampere, and Nordic Society of Gynecologic Oncology NSGO, Finland.

    Siel Olbrecht

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Tina Laga

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium.

    Erwin Sablon

    KU Leuven VIB Center for Cancer Biology, Lab of Translational Genetics, Leuven, Belgium.

    Isabelle Ray-Coquard

    Department of Medical Oncology, Centre Léon Bérard University Claude Bernard, Lyon, and Groupe d’Investigateurs Nationaux pour l’Etude des Cancers Ovariens (GINECO), France.

    Eric Pujade-Lauraine

    Association de Recherche Cancers Gynécologiques (ARCAGY), Paris, France.

    Diether Lambrechts

    KU Leuven VIB Center for Cancer Biology, Lab of Translational Genetics, Leuven, Belgium.

    Toon Van Gorp

    University Hospitals Leuven, Leuven Cancer Institute (LKI), KU Leuven, and Belgium and Luxembourg Gynecologic Oncology Group (BGOG), Leuven, Belgium. Electronic address: toon.vangorp@uzleuven.be.

REFERENCES & ADDITIONAL READING

PubMed

MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.


Advertisement
Advertisement
ad
ad
MORE ARTICLES BELOW

PW Weekly Newsletters

The latest articles and insights from your colleagues in your specialty(ies) of choice.

SUBSCRIBE NOW

View all newsletters

Advertisement